[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"periodontal-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:periodontal-diseases":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,71,0,25,[9,45,70,97,122,149,171,197,217,246,269,293,318,342,367,391,411,437,458,486,518,545,567,593,613],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100539890","hyaluronic-acid-and-polynucleotides-for-supra-bony-defects-100539890",false,"NCT06309719","Hyaluronic Acid and Polynucleotides for Supra-bony Defects","Characterizing the Healing of Periodontal Supra-bony Defects Treated With Hyaluronic Acid and Polynucleotides","Inclusion Criteria:\n\n* Systemically healthy males and females ≥18 years old\n* Stage III or IV periodontitis (Papapanou, Sanz et al. 2018)\n* Presence of supra-bony periodontal defects (i.e., defects where the base of the pocket is located coronal to the alveolar crest and characterized by a predominantly horizontal pattern of tissue destruction) confirmed clinically and radiographically at a minimum of two and a maximum of four adjacent teeth and with a probing pocket depth (PPD) \\> 5 mm, following non-surgical periodontal therapy (NSPT). If \\>4 adjacent teeth exhibited the above clinical and radiographic conditions, the four adjacent teeth showing the greatest overall loss of periodontal attachment were included. Wisdom teeth and second molars will not be considered for the study.\n\nIf defect presents with an intrabony component, this should be ≤2 mm.\n\n* Non-surgical periodontal treatment (step 1 and 2) completed within the previous 4 months\n* Full-mouth bleeding score (FMBS) and full-mouth plaque score (FMPS) ≤20%\n\nExclusion Criteria:\n\n* Teeth with degree III mobility\n* Multi-rooted teeth with grade ≥2 furcation involvement\n* Heavy smokers (≥10 cigarettes a day)\n* Untreated caries or endodontic lesions or abscesses on the teeth involved in the surgery\n* Previous periodontal surgery in the area selected for the study\n* History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures (e.g., mitral valve prolapse, artificial heart)\n* Antibiotic or anticoagulant therapy during the month preceding the baseline exam.\n* History of alcohol or drug abuse\n* Medical history that includes uncontrolled diabetes or hepatic or renal diseases, or other serious medical conditions that can have a negative impact on the periodontal condition\n* In treatment with medications that can severely affect bone metabolism and blood clot formation (e.g., anticoagulants, long-term corticosteroids, bisphosphonates, immunosuppressants)\n* Self-reported pregnancy or lactation.","ALL","18 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this pilot study is to describe the early wound healing molecular events and the vascularization pattern associated with the treatment of supra-bony defects with access flap alone or in association with a combined formulation of hyaluronic acid and polydeoxyribonucleotides gel.",[27,28,29,30,31],"Periodontal Diseases","Wound Heal","Periodontal Inflammation","Periodontal Pocket","Periodontal Attachment Loss","RECRUITING","2026-07-01",{"date":35,"type":36},"2026-07-02","ACTUAL",{"date":38,"type":36},"2024-10-21",{"date":40,"type":21},"2026-12",{"name":42,"class":43},"Queen Mary University of London","OTHER",2,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100527578","changes-in-microbial-status-from-dentate-edentulous-and-after-dental-implant-placement-100527578","NCT06149585","Changes in Microbial Status From Dentate, Edentulous and After Dental Implant Placement","Inclusion Criteria:\n\n1. At least 21 years of age\n2. Diagnosis of Stage III or IV periodontitis based on full mouth probing and full mouth x-rays\n3. Planned for full mouth extraction and replacement by dental implants.\n4. Rehabilitation with Implant supported restorations either maxilla and\u002F or mandible.\n5. At least 2 implants available for examination.\n6. No bone augmentation required.\n\nExclusion Criteria:\n\n1. Conditions requiring chronic routine prophylactic use of antibiotics.\n2. Conditions requiring prolonged use of steroids.\n3. History of leukocyte dysfunction and deficiencies\n4. Bleeding disorders\n5. History of neoplastic disease requiring use of radiation or chemotherapy\n6. Metabolic bone disorders\n7. Uncontrolled endocrine disorder\n8. Use of any investigational drug or device within the 30 day period prior to implant surgery.\n\n10\\. Alcoholism or drug abuse 11. Patient infected with HIV 12. Condition or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, unreliability.\n\nLocal Exclusion Criteria\n\n1. Local inflammation\n2. Mucosal disease such as erosive lichen planus\n3. History of local irradiation therapy\n4. Osseous lesion.\n5. Active infection with suppuration or fistula track.\n6. Persistent intraoral infection different than periodontitis",true,"21 Years",{"count":54,"type":21},12,"OBSERVATIONAL","The objectives of this study are to analyze the oral microbiome modulations occurring during the transition from partial (with some residual teeth) to full edentulous (without remaining teeth) status and implant placement in subjects affected by severe periodontitis; to evaluate if microbiome changes in relation to the used of different implant material\u002Fsurface; and to assess the variance of the changes to determine the sample size for future longitudinal prospective studies.",[58,27,59,60],"Edentulous Mouth","Periodontitis, Adult","Microbial Colonization","2026-06-29",{"date":33,"type":36},{"date":64,"type":36},"2023-08-16",{"date":66,"type":21},"2028-05-01",{"name":68,"class":43},"Case Western Reserve University",1,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":79,"conditions":80,"keywords":81,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":44},"100605841","longitudinal-follow-up-study-to-determine-the-predictive-ability-of-a-panel-of-biomarkers-in-saliva-in-healthy-and-periodontally-affected-patients-100605841","NCT07167771","LONGITUDINAL FOLLOW-UP STUDY TO DETERMINE THE PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED PATIENTS","FLOE_long","Inclusion Criteria:\n\n* Participants from the cohort involved in the previous cross-sectional study (code 23\u002F481-E).\n* Adults (≥ 18-year-old)\n* Being able to sign an informed consent form\n* Willing to participate in this observational investigation\n* Diagnosed as periodontally healthy, gingivitis, treated periodontitis patient (stable \u002F unstable), periodontitis stages I \\& II, or periodontitis stages III and IV (Papapanou et al. 2023) in the previous cross-sectional study (code 23\u002F481-E)\n\nExclusion Criteria:\n\n* Patients fitting to all the above inclusion criteria will be excluded from the study if unable to attend to the study-related procedures.",{"count":78,"type":21},100,"Objective: The main aim of this longitudinal clinical study is to evaluate the predictive ability of a panel of salivary biomarkers in determining periodontal health status in 2 years follow up in a group of healthy and periodontally affected individuals.\n\nMaterial and methods: In this longitudinal, observational follow-up study, patients previously enrolled in a cross-sectional study at the Periodontal Postgraduate Clinic, University Complutense of Madrid, will be re-evaluated over a 2-year period. Participants (≥18 years) will be categorized into diagnostic groups based on the 2018 classification of periodontal diseases, including periodontally healthy, gingivitis, treated periodontitis (stable\u002Funstable), and various stages of periodontitis. The study will include follow-up visits at 1 and 2 years. At each visit, participants will undergo a comprehensive medical examination to assess age, gender, weight, height, waist circumference, blood pressure, temperature, smoking and alcohol history, systemic health, and HbA1c levels. A periodontal examination will be performed at six sites per tooth, and clinical parameters including plaque, bleeding on probing, probing depth, recession, and tooth loss will be recorded. Saliva and subgingival plaque samples will be collected for biomarker and microbiological analysis. Salivary biomarkers will be measured using multiplex immunoassays, and bacterial quantification will be performed by multiplex qPCR. Data analyses: Descriptive statistics will be used to report the clinical variables and patients will be grouped according to the pre-established diagnostic categories (periodontally healthy, gingivitis, treated periodontitis patient. In order to determine the possible statistical relationship with the medical, biochemical and microbiological variables assessed, a crude bivariate analysis will first be performed by applying a mean comparison test for quantitative variables (ANOVA) and a proportion comparison test for categorical variables (Chi-square). Subsequently, those variables identified as relevant in the crude analyses will be included as confounding and\u002For interaction factors in a binary logistic regression model, considering the presence of periodontitis as a response variable, in order to obtain crude and adjusted OR values, together with their corresponding 95% CIs. Based on the results obtained in the biomarker analysis, a relevant statistical analysis will be performed, taking into account all the variables collected in the study. For periodontitis cases, treatment response over time will be analyzed, with subgroup comparisons between responders and non-responders.",[27],[82,83,84,85,86,87,88],"periodontal diseases","saliva","biomarkers","prediction","periodontopathogens","interleukin 1","MMP-8","2026-06-26",{"date":61,"type":36},{"date":92,"type":36},"2025-10-01",{"date":94,"type":21},"2028-10",{"name":96,"class":43},"Universidad Complutense de Madrid",{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":51,"sex":17,"minAge":52,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":69},"100645188","influence-of-re-evaluation-timing-after-phase-i-periodontal-therapy-on-clinical-and-periodontal-outcomes-100645188","NCT07678125","Influence of Re-evaluation Timing After Phase I Periodontal Therapy on Clinical and Periodontal Outcomes.","Influence of Re-evaluation Timing After Phase I Periodontal Therapy on Clinical and Periodontal Outcomes. A Split-mouth Study","Inclusion Criteria:\n\n* Patients above 18 yrs\n* Patients that are systemically healthy\n* Patients diagnosed as Stage III or Stage IV Periodontitis\n* Patients willing to participate in the study and provide informed consent.\n* Patients with no recent history of periodontal therapy\n* Presence of ≥20 natural teeth\n\nExclusion criteria:\n\n* Patients with a history of medical conditions or diseases that may affect healing or periodontal tissues.\n* Patients who are pregnant\n* Patients on Drugs\u002Fmedication that may affect the periodontal tissue\n* Smokers or tobacco users\n* Patients that cannot complete the 12-week follow-up period","70 Years",{"count":20,"type":21},[24],"Periodontal disease remains a highly prevalent chronic inflammatory condition affecting the supporting structures of the teeth and is a leading cause of tooth loss worldwide. Contemporary periodontal therapy is structured into sequential phases, with non-surgical periodontal therapy (NSPT) forming the cornerstone of initial management. Following this phase, re-evaluation of periodontal status is critical to determine treatment outcomes and guide further intervention, including surgical therapy if required (1,2).\n\nRe-evaluation phase serves multiple purposes: it allows assessment of tissue response to therapy, measurement of reductions in probing pocket depth (PPD), gains in clinical attachment level (CAL), and evaluation of patient compliance with oral hygiene practices. It also aids in identifying residual pockets or persistent inflammation that may necessitate additional treatment (1,3). Despite its clinical importance, the optimal timing of re-evaluation remains inconsistently defined in the literature (1). Generally, current literature utilizes a timing frame from 1-3 months; up to 9 months (3,4). Current clinical guidelines, including those from the European Federation of Periodontology (EFP), generally recommend assessing whether the end points have been achieved; no periodontal pockets ≥ 5mm with bleeding on probing and no pocket ≥ 6mm (5).\n\nEmerging evidence suggests that certain clinical improvements, particularly reductions in inflammation and bleeding on probing (BOP), may occur as early as 4 weeks following therapy, raising questions about whether earlier re-evaluation could be clinically beneficial (2,3). Early reassessment may allow for more timely identification of non-responding sites, enabling prompt intervention and potentially improving overall treatment outcomes. Conversely, other studies indicate that full periodontal healing and maturation of tissues may require longer periods, supporting delayed re-evaluation intervals (1,2,3).\n\nFurthermore, patient-related factors such as systemic health, smoking status, and baseline disease severity may influence healing dynamics and thus the appropriate timing for reassessment (1). The heterogeneity of these factors highlights the potential need for a more individualized approach to re-evaluation rather than a fixed universal timeframe.\n\nDespite these considerations, there is a notable lack of high-quality comparative studies directly evaluating short-term versus conventional re-evaluation intervals following NSPT. Most available studies focus on treatment outcomes rather than the timing of reassessment itself. This creates a significant gap in the literature, particularly regarding whether earlier re-evaluation could enhance clinical decision-making, improve patient outcomes, or optimize resource utilization in clinical practice.\n\nIn addition, with increasing emphasis on minimally invasive and patient-centered care, there is a growing need to refine periodontal treatment protocols to ensure efficiency without compromising effectiveness. Determining the optimal timing of re-evaluation could contribute to improved treatment planning, reduced disease progression, and enhanced long-term periodontal stability.\n\nTherefore, this study aims to address this gap by investigating the effectiveness and clinical implications of shorter re-evaluation intervals following periodontal therapy, compared to conventional timeframes.",[27,109,110],"Periodontitis (Stage 3)","Subgingival Debridement",[112],"periodontal disease","NOT_YET_RECRUITING","2026-06-25",{"date":33,"type":36},{"date":117,"type":21},"2026-06-01",{"date":119,"type":21},"2027-02-15",{"name":121,"class":43},"Gulf Medical University",{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":132,"conditions":133,"keywords":136,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":69},"100644292","evaluation-of-the-effect-of-hyperuricemia-on-alveolar-bone-loss-100644292","NCT07666126","Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss","Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss and Oxidative Stress","Inclusion Criteria:\n\n* Being between 18 and 65 years of age\n* Being systemically healthy or diagnosed with hyperuricemia\n* Having at least 20 natural teeth\n* Being periodontally healthy or diagnosed with periodontitis\n\nExclusion Criteria:\n\n* Diabetes, cardiovascular disease, osteoporosis, chronic kidney disease, metabolic syndrome, and obesity are systemic diseases that may affect purine metabolism.\n* Smoking\n* Pregnancy or lactation\n* Having received periodontal treatment within the last 3-6 months\n* Use of antibiotics, anti-inflammatory drugs, or uric acid-lowering drugs\n* Presence of systemic diseases that may affect purine metabolism","65 Years",{"count":131,"type":21},80,"Periodontitis is a multifactorial disease characterized by chronic inflammation of the gum tissue and alveolar bone destruction, and is known to be associated with various systemic diseases. Hyperuricemia, on the other hand, is a metabolic condition characterized by increased serum uric acid levels and can affect inflammation, oxidative stress, and bone metabolism. In recent years, the relationship between hyperuricemia and periodontal diseases has been increasingly investigated, but the biological mechanisms of this relationship have not yet been fully elucidated. Therefore, this study aimed to determine whether there is a relationship between hyperuricemia and periodontitis and to reveal the possible pathophysiological mechanisms of this relationship, which are shaped by inflammation, oxidative stress, and bone metabolism.\n\nA total of 80 individuals aged 18-65 years will be included in this clinical observational study. The periodontal status of the participants will be assessed using clinical periodontal parameters such as probing pocket depth, clinical attachment loss, plaque index, gingival index, and bleeding on probing. Participants will be divided into four groups according to their periodontal status and the presence of hyperuricemia: individuals with periodontitis and hyperuricemia, individuals with periodontally healthy and hyperuricemia, individuals with periodontitis but without hyperuricemia, and individuals with periodontally healthy and without hyperuricemia. Gingival crevicular fluid and serum samples will be taken from the participants. In these samples, receptor-mediated nuclear factor kappa B ligand, osteoprotegerin, total antioxidant status, total oxidant status, oxidative stress index, interleukin-1 beta, interleukin-10, interleukin-18, and nucleotide-binding oligomerization domain-like receptor protein 3 levels will be analyzed. This study is considered unique because it examines the relationship between hyperuricemia and periodontitis by evaluating inflammation, oxidative stress, and bone metabolism parameters together.",[27,134,135],"Hyperuricemia","Oxidative Stress",[112,137,138,139,140],"hyperuricemia","oxidative stress","alveolar bone loss","inflammation","2026-06-23",{"date":89,"type":36},{"date":144,"type":21},"2026-06-10",{"date":146,"type":21},"2026-10-01",{"name":148,"class":43},"Recep Tayyip Erdogan University Training and Research Hospital",{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":69},"100642636","evaluation-of-the-impact-of-periodontitis-and-its-treatment-on-swallowing-functions-and-oral-quality-of-life-100642636","NCT07651579","Evaluation of the Impact of Periodontitis and Its Treatment on Swallowing Functions and Oral Quality of Life","FI-PAROCROC","Inclusion Criteria:\n\n* Patients treated at the university hospital and diagnosed with periodontitis\n* Adult patients who have provided informed consent\n* Patients enrolled in a social security system\n* Patients who speak and understand French.\n\nExclusion Criteria:\n\n* Minors\n* Pregnant or breastfeeding patients\n* Patients under legal protection or conservatorship\n* Patients who refuse to participate in the study",{"count":157,"type":21},44,[24],"The objective of this single-center prospective study is to evaluate the impact of periodontal treatment on masticatory performance in patients with periodontitis.\n\nParticipants will be asked to complete several questionnaires related to their oral health and quality of life. Functional masticatory tests and salivary flow measurements will also be performed.",[161,27,162],"Periodontitis","Quality of Life","2026-06-11",{"date":165,"type":36},"2026-06-16",{"date":117,"type":21},{"date":168,"type":21},"2028-06-01",{"name":170,"class":43},"University Hospital, Clermont-Ferrand",{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":104,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":185,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":69},"100643649","the-effect-of-vitamin-d-supplementation-on-the-anti-inflammatory-response-in-periodontal-diseases-100643649","NCT07636733","The Effect of Vitamin D Supplementation on the Anti-inflammatory Response in Periodontal Diseases","The Effect of Vitamin D Levels and Supplementation on Anti-inflammatory Response in Periodontal Disease: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Study groups will be formed according to the 2017 Periodontal Disease Classification. Accordingly:\n* Periodontally healthy; absence of bleeding on probing, erythema, edema, patient symptoms, attachment, and bone loss\n* Gingivitis; patients with an average gingival index ≥0.5 according to Löe and Silness\n* Stage I-II periodontitis; patients with CAL 1-2 or 3-4 mm and a maximum PPD ≤5 mm, showing radiographic horizontal bone loss up to the coronal third of the root (15%-33%), but without tooth loss due to periodontitis\n* Stage III-IV periodontitis; Stage 3 and 4 patients with ≥15 teeth in their mouth, with CAL ≥5 and PPD ≥6 in at least 6 areas, and radiographic bone loss extending to the middle or apical third of the root.\n\nExclusion Criteria:\n\n* Individuals who have undergone periodontal treatment in the last 6 months, have systemic diseases (such as diabetes, parathyroid and thyroid-related endocrine diseases) that may affect periodontal status, patients with chronic liver disease, hypoparathyroidism and renal failure, those who have been using medications that may affect periodontal response (aspirin, non-steroidal anti-inflammatory drugs or steroids) for a long time, those who are using additional vitamin D or calcium supplements in the pre-study phase, those who are pregnant or breastfeeding, and those with hypercalcemia and malabsorption syndrome will not be included in the study.",{"count":179,"type":21},120,[24],"A review of the literature revealed that while there are studies investigating the relationship between vitamin D and periodontal disease, there are no studies investigating the anti-inflammatory effect of vitamin D on periodontal disease. Investigators hypothesized that the increased incidence of periodontal disease in individuals with vitamin D deficiency might be due not only to pro-inflammatory effects but also to impaired bone metabolism and a decrease in the anti- inflammatory mechanism. Investigators aimed to determine this by comparing serum and DOS levels of 1,25-dihydroxyvitamin D (1,25(OH)2D), 25-hydroxyvitamin D (25(OH)D3), Receptor activator nuclear kappa B ligand (RANKL), osteoprotegerin (OPG), Tumor Necrosis Factor Related Apoptosis induced Ligand (TRAIL), Developmental endothelial locus (Del)-1, Lipoxin, Resolvin, interleukin (IL)-10, and transforming growth factor-β (TGF-β).\n\nThe study will include 120 individuals who are systemically healthy based on clinical and radiographic examinations and diagnosed with Stage I-II periodontitis, Stage III-IV periodontitis, chronic gingivitis, and periodontally healthy. Periodontal clinical parameters (Probing pocket depth (PPD), Clinical attachment level (CAL), Bleeding on probing (BOP), Plaque index (PI), Gingival index (GI)) will be recorded three times: before treatment, and 6 and 12 weeks after treatment. Gingival crevicular fluid (GCF) and serum samples will be collected from participants at baseline and 12 weeks later for biochemical analysis.",[27,183,184],"Gingivitis","Vitamin D Deficiency",[186,187,188,189],"periodontitis","gingivitis","Vitamin D","anti-inflammatory","2026-06-08",{"date":144,"type":36},{"date":193,"type":36},"2026-06-03",{"date":195,"type":21},"2026-10-16",{"name":148,"class":43},{"id":198,"slug":199,"hasResults":12,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":212,"completionDateStruct":213,"leadSponsor":215,"locationsCount":69},"100637417","tedlar-bag-stability-of-volatile-sulfur-compounds-for-remote-halitosis-diagnosis-100637417","NCT07602309","Tedlar Bag Stability of Volatile Sulfur Compounds for Remote Halitosis Diagnosis","Relevance of Using Tedlar Bags for the Remote Evaluation of the Stability of Volatile Sulfur Compounds in Gaseous Samples for the Diagnosis of Halitosis","Malodorix","Inclusion Criteria:\n\nAdult subject, male or female\n\n* Subject affiliated with a health insurance system\n* Subject able to sign the non-opposition form\n* Subject attending a consultation at UF8607 for diagnosis and treatment of a periodontal condition\n\nExclusion Criteria:\n\n* \\- Subject under legal protection (judicial safeguard)\n* Subject under guardianship or curatorship\n* Pregnancy or breastfeeding\n* Inability to provide the subject with informed information (e.g., emergency situation, comprehension difficulties)\n* Subject currently enrolled in another clinical research protocol or in an exclusion period",{"count":78,"type":21},[24],"Halitosis, or bad breath, affects about 30% of people worldwide and is most often caused by oral diseases such as periodontitis. To diagnose it, dentists usually perform a clinical examination and measure specific gases in the breath called volatile sulfur compounds (VSCs), which are responsible for bad odor. However, the equipment needed for this analysis is not widely available, forcing many patients to travel long distances. This study aims to determine whether breath samples can be collected and analyzed later, making remote diagnosis possible. Specifically, it evaluates whether the levels of these gases remain stable for up to 7 days after collection, with a variation of less than 20% considered acceptable. To do this, 100 adult patients with periodontal conditions will be included in a single-center study.\n\nDuring a single visit, patients will provide breath samples by exhaling into a special Tedlar bag and a syringe, which will then be analyzed immediately and again after 7 days using a device called OralChroma. Afull periodontal examination will also be performed, and patient information such as age and risk factors will be collected. The study will also examine how gas levels change over time and whether they are linked to gum disease. If the results confirm that the samples remain stable, this approach could allow patients to collect their breath at home and receive a diagnosis remotely, reducing the need for travel and improving access to care.",[209,27],"Halitosis","2026-05-29",{"date":193,"type":36},{"date":117,"type":21},{"date":214,"type":21},"2027-06-01",{"name":216,"class":43},"University Hospital, Strasbourg, France",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":231,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":69},"100505212","clinical-effectiveness-of-biologic-agents-as-an-adjunct-to-non-surgical-periodontal-therapy-of-intrabony-defects-100505212","NCT05858411","Clinical Effectiveness of Biologic Agents as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects","Evaluation of the Efficacy of rhPDGF, L-PRF and EMD as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects: a Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with a diagnosis of periodontitis stage III or IV (grades A to C),\n* non-smokers or former smokers who quit at least 1 year ago, and\n* had not received any periodontal treatment in the 3 months prior to recruitment;\n* Presence of at least 1 Infrabony defect (PPD ≥ 5 mm with infrabony defect depth of ≥3mm at screening radiograph);\n* One and two wall infrabony defects at screening radiograph and periodontal charting.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Presence of uncontrolled systemic diseases that could affect treatment outcomes such as diabetes mellitus with an HbA1C\\>7%, rheumatoid arthritis or any form of immunosuppression;\n* Subjects requiring antibiotic prophylaxis;\n* 3-wall infrabony defects;\n* Patients that had received systemic or local delivery of antibiotic therapy 6 weeks before enrollment;\n* Presence of furcation defect;\n* Chronic intake of NSAIDs or steroids, currently;\n* Patients undergoing orthodontic treatment, having removable prosthetic appliances, pregnancy, tumors of the oral cavity or the presence of any psychiatric condition that could affect participation.",{"count":225,"type":21},88,[24],"The aim of the present study is to clinically and radiographically compare the efficacy of recombinant human platelet-derived growth factor (rhPDGF), Leukocyte-Platelet Rich Fibrin (L-PRF) and Enamel Matrix Derivatives (EMD) in intrabony defects following minimally invasive non surgical peridoontal therapy (MINST).\n\nThis study will be designed as a randomized clinical trial of 12-month duration. A total of 88 patients (each with a single infrabony defect) will be recruited and randomly equally distributed into 4 groups: an experimental group treated with MINST and rhPDGF, a second group treated with MINST + L-PRF, a third group treated with MINST and EMD and and a control group treated with MINST alone.\n\nEach defect will be treated with an ultrasonic scaler with dedicated thin tips for supra- and subgingival debridement associated with hand instrumentation under local anesthesia. Caution will be taken to preserve the stability of soft tissues. Following MINST experimental and control sites will be randomly chosen. The test sites will be treated by inserting a collagen plug soaked for at least 15 minutes in a 1.5cc solution containing hPDGF-BB. In the second group the infrabony defects will be treated with MINST and L-PRF. In the third group the infrabony defects will be treated with MINST and EMD. The control group will be treated with MINST alone.\n\nPre- and post-treatment clinical measurements were performed by an examiner blinded to the treatment modalities using a graded periodontal probe (HuFriedy UNC 15). Before the treatment and at 6 and 12 months post-treatment, all patients were examined by measuring the clinical attachment level, probing depth, gingival recession, full-mouth plaque score and bleeding on probing.\n\nStandardized radiographs of selected study sites will be taken at baseline and at the 6 and 12 months follow-up visits using the long-cone technique with a customized holder and a thermoplastic occlusal reference to allow reproducible positioning. All radiographs will be analysed by a dedicated dental software (Carestream Dental LLC Atlanta, GA, USA) to make linear measurements. The defect bone level (DBL), the defect angle (DA), the intra- and suprabony components of the defect and the radiographic defect area (RDA) will be evaluated.",[27,31,229,230],"Pocket, Periodontal","Intrabony Periodontal Defect",[232,233,234,235,236],"rhPDGF","Growth factors","Periodontal regeneration","L-PRF","Enamel Matrix Derivatives","2026-05-25",{"date":239,"type":36},"2026-05-28",{"date":241,"type":36},"2023-01-08",{"date":243,"type":21},"2027-09-01",{"name":245,"class":43},"G. d'Annunzio University",{"id":247,"slug":248,"hasResults":12,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":256,"conditions":257,"keywords":258,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":4},"100639708","profiling-gingival-crevicular-fluid--catenin-level-with-8-ohdg-and-total-antioxidants-capacity-during-healing-of-periodontal-pockets-a-3-month-clinical-trial-100639708","NCT07596667","Profiling Gingival Crevicular Fluid β-Catenin Level With 8-OHdG and Total Antioxidants Capacity During Healing of Periodontal Pockets: A 3-month Clinical Trial","Inclusion criteria:\n\n* patients over 18 years old\n* patients with periodontal pockets depth more than 4 mm\n\nExclusion criteria:\n\n* Pregnant women\n* patients taking antibiotic within the last three months\n* Patients with systemic disease ( Diabetes mellitus)","60 Years",{"count":254,"type":21},21,[24],"Background: To profile gingival crevicular fluid (GCF) β-Catenin, 8-OHdG, and total antioxidants capacity (TAC) in periodontitis patients during healing of periodontal pockets following non-surgical periodontal therapy (NSPT).Methods: Periodontitis patients (n = 21) will included in this clinical trial. Clinical periodontal parameters will recorded and GCF samples will collected from randomly selected 4-6 mm periodontal pockets at baseline (T0) as well as 4 weeks (T1) and 12 weeks (T2) after NSPT. GCF levels of β-catenin, 8-OHdG, and TAC will be assayed by enzyme linked immunosorbent assay (ELISA).",[59,27],[186,259],"non surgical periodontal therapy","2026-05-18",{"date":262,"type":36},"2026-05-19",{"date":264,"type":21},"2026-07-15",{"date":266,"type":21},"2026-12-01",{"name":268,"class":43},"Zeyad Nazar",{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":17,"minAge":276,"maxAge":277,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":44},"100566526","an-evaluation-of-the-effect-of-the-erchonia-fx-405-laser-as-an-adjunctive-treatment-of-periodontitis-100566526","NCT06656325","An Evaluation of the Effect of the Erchonia FX-405 Laser as an Adjunctive Treatment of Periodontitis","An Evaluation of the Effect of the Erchonia Corporation FX-405 Laser as an Adjunctive Treatment of Periodontitis","Inclusion Criteria:\n\n* Subject has voluntarily signed a written informed consent form.\n* Male or female 22 to 75 years of age, inclusive.\n* Subject has no evidence of Localized Aggressive Periodontitis.\n* Tooth loss due to periodontitis of ≤ 4 teeth.\n* Two or more teeth with the following characteristics: Non 3rd molar, Periodontitis: Stage III (Severity) according to the Interdental CAL (at site of greatest loss) and RBL, as classified by the American Academy of Periodontology (AAP), No evidence of caries, No abscess infection, No previous periodontal surgery within the prior 12 months\n* Subject agrees to adhere to study provided home care instructions to maintain adequate oral hygiene during the study duration.\n* Subject agrees to refrain from the use of smokeless chewing tobacco for the study duration.\n* Subject agrees to refrain from exceeding 40 milligrams per day of inhaled nicotine, encompassing cigarettes, electronic cigarettes, and cigars.\n* Subject agrees to refrain from engaging in any other treatments for his or her periodontitis that is outside the scope of this study during his or her participation in this study\n\nExclusion Criteria:\n\n* Gingival recession which may be genetic, induced secondary to orthodontic treatment, induced secondary to frenulum attachments, or present as a result of dental malocclusion.\n* History of oral cancer or HIV in the last 6 months\n* Pregnant or intending to become pregnant in the next 8 months.\n* Sensitivity to, or contraindication for, light therapy.\n* Currently enrolled in a clinical study of an investigational drug or device.","22 Years","75 Years",{"count":279,"type":21},70,[24],"The purpose of this clinical study is to determine the effectiveness of the Erchonia® FX-405 (manufactured by Erchonia Corporation (the Company) in providing a noninvasive adjunctive treatment in combination with periodontal scaling and root planing for improving the treatment of periodontal disease.",[27,161,283],"Gum Disease","2026-05-14",{"date":260,"type":36},{"date":287,"type":36},"2025-01-01",{"date":289,"type":21},"2027-08-01",{"name":291,"class":292},"Erchonia Corporation","INDUSTRY",{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":301,"conditions":302,"keywords":304,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":69},"100638179","candida-albicans-in-syrian-patients-with-periodontitis-100638179","NCT07574827","Candida Albicans in Syrian Patients With Periodontitis","Prevalence and Impact of Candida Albicans in Syrian Patients With Periodontitis: A Cross-Sectional Study","Inclusion Criteria:\n\n* Patients aged 18 years and older.\n* Diagnosed with chronic periodontitis based on clinical examination (attachment loss, probing depth).\n* Consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients with systemic diseases affecting oral health (e.g., diabetes, immunosuppressive conditions).\n* Recent antibiotic or antifungal treatment within the last three months.",{"count":78,"type":21},"Periodontitis is a significant oral health issue characterized by inflammation and destruction of the supporting structures of the teeth. Recent research has indicated that Candida albicans, a common fungal pathogen, may play a role in the exacerbation of periodontal diseases. This study aims to investigate the prevalence and impact of Candida albicans in Syrian patients diagnosed with periodontitis, contributing to a better understanding of its role in oral health within this population.",[303,27,161],"Periodontal Disease",[305,306,161,307,308],"Candida Albicans","Candida","Sabouraud Dextrose Agar","Culture","2026-05-02",{"date":311,"type":36},"2026-05-08",{"date":313,"type":36},"2026-04-07",{"date":315,"type":21},"2026-09",{"name":317,"class":43},"Al-Hawash Private University",{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":325,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":327,"conditions":328,"keywords":329,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":69},"100624493","development-of-a-self-assessment-tool-for-personalized-preventive-periodontal-care-among-the-saudi-population-using-semi-supervised-learning-100624493","NCT07410351","Development of A Self-Assessment Tool for Personalized Preventive Periodontal Care Among the Saudi Population Using Semi-Supervised Learning","Development and Validation of a Self-assessment Tool for Periodontal Disease Risk Assess Among the Saudi Population Using Semi-supervised Learning","Inclusion Criteria:\n\n* Adult aged 18 years or older\n* Able to read and understand the study information and provide informed consent\n* Able to complete the online questionnaire independently (on a smartphone\u002Ftablet\u002Fcomputer)\n* Willing to undergo a same-visit clinical periodontal examination\n* Has natural teeth present (dentate)\n\nExclusion Criteria:\n\n* Completely edentulous (no natural teeth)\n* Currently undergoing active periodontal treatment (e.g., scaling and root planing) or received periodontal therapy within the past \\[6 months\\]\n* Took systemic antibiotics within the past \\[3 months\\]\n* Unable to complete the questionnaire or examination due to cognitive impairment, severe illness, or communication barriers that prevent informed consent\n* Refuses or is unable to tolerate the periodontal clinical examination",{"count":326,"type":21},393,"This observational study will collect labeled data to assess the accuracy of an online periodontal self-assessment tool in adults. Participants will complete the questionnaire and then undergo a clinical periodontal examination during the same visit. The study will compare questionnaire-based results with clinical examination results to evaluate diagnostic accuracy and agreement.",[27,161,183],[330,331,332],"Periodontal diseases","risk assessment","self-report","2026-04-28",{"date":335,"type":36},"2026-05-05",{"date":337,"type":36},"2026-02-15",{"date":339,"type":21},"2026-10-15",{"name":341,"class":43},"Universiti Sains Malaysia",{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":350,"enrollmentInfo":351,"targetDuration":4,"studyType":22,"phases":353,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":69},"100413909","phase-4-antibiotics-as-adjuncts-to-periodontal-therapypharmacokinetic-considerations-and-dosing-strategies-100413909","NCT04669717","Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies","Pharmacokinetic Considerations and Dosing Strategies of Amoxicillin and Metronidazole or Azithromycin as Adjunct to Non-surgical Periodontal Therapy. A Randomized,6-month, Parallel-group, Clinical Trial.","AMA","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Aged 18-80 years old with need of periodontal treatment associated with adjunctive antibiotic therapy\n* Presence of at least 30% of the teeth in the mouth with PD\\>6mm and BOP\n\nExclusion Criteria:\n\n* Persons with systemic illnesses (uncontrolled diabetes mellitus, cancer, human immunodeficiency virus, bone metabolic diseases or disorders that compromise wound healing, radiation, or immunosuppressive therapy)\n* Pregnancy or lactation\n* Persons who had taken AB within the previous 2 months\n* Persons who are taking nonsteroidal anti-inflammatory drugs\n* Persons who have a confirmed or suspected intolerance to 5-nitroimidazole derivatives or amoxicillin or macrolides\n* Previous periodontal therapy the last 1 year\n* Known or suspected non-compliance, drug or alcohol abuse\n* Inability to follow due to language problems, psychological disorders, dementia, etc. of the participant\n* Participants not willing to attend regular dental maintenance visits and follow-up evaluations\n* Participation in another study with investigational drug within the 30 days preceding and during the present study","80 Years",{"count":352,"type":21},45,[354],"PHASE4","Periodontitits is a bacteria induced inflammatory disease that destroys the supporting tissues of the tooth and leads to tooth loss. Treatment consists mainly of the mechanical cleaning of the tooth surfaces in order to remove the bacterial deposits (plaque and calculus). This procedure can reduce the level of pathogenic bacteria but it can not eradicate them. In severe cases, for the complete resolution of the disease, the elimantion of certain species of bacteria is needed. In order to achieve that, the combination of different regimens of antibiotics adjunctive to the mechanical treatment has been proposed. However, dosage and duration of antimicrobial therapy should be optimal and not excessive as issues may arise related to increased antimicrobial resistance in the population and the individual due to habitual prescription of wide-spectrum antibiotic regimens, horizontal gene transfer and genetic mutation.\n\nIn the present study, in an effort to optimize the dosage and duration of the antimicrobial regimen, we will determine the pharmacokinetics (PK) and pharmacodynamic (PD) properties of the MET-AMO combination and of AZI in Gingival Crevicular Fluid (GCF), saliva and serum in severe periodontitis patients during and after either a 3-day or a 7-day course of treatment.",[27,357,358],"Antibiotics","Pharmacokinetics",{"date":360,"type":36},"2026-04-29",{"date":362,"type":36},"2021-09-01",{"date":364,"type":21},"2028-12-01",{"name":366,"class":43},"University of Geneva, Switzerland",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":51,"sex":17,"minAge":373,"maxAge":4,"enrollmentInfo":374,"targetDuration":375,"studyType":55,"phases":4,"briefSummary":376,"conditions":377,"keywords":379,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":389,"locationsCount":4},"100624152","3d-printed-customized-bone-graft-for-alveolar-regeneration-longitudinal-cohort-evaluation-100624152","NCT07405918","3D Printed Customized Bone Graft for Alveolar Regeneration: Longitudinal Cohort Evaluation","Inclusion Criteria:\n\n* Systemically healthy individuals\n* over 18 years of age\n* Subjects that received regenerative surgical treatment by customized 3D printed blocks.\n* Subjects must agree to participate in the study and agree to sign the Informed Consent.\n\nExclusion Criteria:\n\n* Subjects with ilness that avoid their presence to the clinical evaluation\n* ISubjects who have lost the customized blocks\n* Subjects who do not agree to participate in the study will be excluded.","15 Years",{"count":78,"type":21},"6 Years","This study will evaluate the behavior of the implant-supported restorations (prosthesis) placed into the areas grafted with the 3D printed customized bone (personalized graft produced to fit a specific bone defect), as well as the volume contraction of the printed bone.",[27,378],"Periodontal Bone Loss",[380,381,382,383],"Personalized bone graft","3D printed customized bone block","Guided Bone Regeneration","Personalized Medicine","2026-04-26",{"date":333,"type":36},{"date":387,"type":21},"2026-05-01",{"date":266,"type":21},{"name":390,"class":43},"University of Guarulhos",{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":51,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":69},"100633768","oral-hygiene-periodontal-status-and-quality-of-life-100633768","NCT07530978","ORAL HYGIENE, PERIODONTAL STATUS AND QUALITY OF LIFE","EVALUATION OF THE EFFECT OF INDIVIDUALS' ORAL HYGIENE HABITS AND PERIODONTAL STATUS ON QUALITY OF LIFE","Inclusion Criteria:\n\n* Individuals aged 18 years and older\n* Patients presenting to the Department of Periodontology Individuals willing to participate and provide informed consent\n\nExclusion Criteria:\n\n* Use of antibiotics or anti-inflammatory drugs within the last 3 months\n* History of periodontal treatment within the last 6 months\n* Pregnancy or lactation\n* Individuals unable to complete the questionnaire",{"count":399,"type":21},160,"This cross-sectional study aims to evaluate the relationship between oral hygiene habits, periodontal status, and oral health-related quality of life in adult individuals. A total of approximately 160 participants attending the Department of Periodontology will be included. Periodontal status will be assessed using standard clinical parameters, including probing depth, clinical attachment loss, bleeding on probing, and plaque index. In addition, the Periodontal Inflamed Surface Area (PISA) will be calculated to quantify inflammatory burden. Oral health-related quality of life will be evaluated using the OSHIP-Perio questionnaire, a validated patient-reported outcome measure specific to periodontal conditions. The study will investigate the association between clinical periodontal findings, oral hygiene practices, and quality of life outcomes. The findings are expected to provide a comprehensive understanding of both clinical and patient-centered aspects of periodontal disease and contribute to improved individualized treatment approaches.",[27,183,161],"2026-04-25",{"date":404,"type":36},"2026-04-30",{"date":406,"type":36},"2025-10-15",{"date":408,"type":21},"2026-06-15",{"name":410,"class":43},"Abant Izzet Baysal University",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":69},"100634170","characterization-of-jak1-and-jak2-activation-in-gingival-tissues-during-homeostasis-and-periodontitis-100634170","NCT07536204","Characterization of JAK1 and JAK2 Activation in Gingival Tissues During Homeostasis and Periodontitis","Unraveling the Role of JAK1 and JAK2 Pathway in Periodontitis: Drivers of Immunopathology and Possible Therapeutic Targets","Inclusion Criteria:\n\n* Adults\n* Sistemically healthy\n\nExclusion Criteria:\n\n* Active Maliganancy\n* History of radiation to the head-neck region\n* Chemotherapy or radiation within the last 5 years\n* History of hepatitis B\u002FC or HIV infection\n* Autoimmune diseases\n* Diagnosis of diabetes\n* Pregnancy or lactation\n* More than 3 hospitalizations over the last 3 years\n* Use of systemic antibiotics over the last 3 months\n* Use of systemic corticosteroids or immunosuppressants over the last 3 months\n* Use of cytokine therapy over the last 3 months\n* Use of large doses of pre\u002Fprobiotic supplements over the last 3 months\n* Smoke more than 10 cigarettes per day",{"count":419,"type":21},30,"The goal of this observational study is to examine JAK1\u002F2 pathway activation in gingival tissues from adults with healthy gingiva and those with inflamed gingiva (periodontitis). The main question it aims to answer is:\n\nIs the JAK1\u002F2 pathway overactivated in periodontitis compared to health?\n\nParticipants with healthy gingiva and periodontitis will donate gingival tissue to study the JAK1\u002F2 pathway. All participants wil receive diagnosis and treatment of the gingival condition.",[161,27,29,422,31],"Gingival Diseases",[424,425,161,426,427],"JAK1","JAK2","Gingiva","Inflammation","2026-04-10",{"date":430,"type":36},"2026-04-17",{"date":432,"type":36},"2023-06-01",{"date":434,"type":21},"2027-03-31",{"name":436,"class":43},"University of Chile",{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":51,"sex":17,"minAge":444,"maxAge":129,"enrollmentInfo":445,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":447,"conditions":448,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":4},"100631750","klotho-gene-red-complex-bacteria-and-periodontal-viruses-in-patients-with-and-without-periodontitis-and-acute-coronary-syndrome-100631750","NCT07504744","Klotho Gene, Red Complex Bacteria and Periodontal Viruses in Patients With and Without Periodontitis and Acute Coronary Syndrome","Evaluation of the Expression of Klotho Gene and Its Protein Level, Determination of Red Complex Bacteria, and the Estimation of Periodontal Viruses in Patients With and Without Periodontitis and Acute Coronary Syndrome","Inclusion Criteria:\n\n1. Patients willing to participate in the study.\n2. Male and female patients within the age group of 30-65 years.\n3. Patients having ≥ 10 remaining natural teeth.\n4. No history of long-term antibiotic use in past 6 months.\n\nExclusion Criteria:\n\n1. Subjects with systemic conditions such as type I and type I diabetes mellitus, respiratory diseases, renal disease, liver disease, rheumatoid arthritis, allergy, advanced malignancies\u002Fneoplasm and HIV infection will be excluded from the present investigation.\n2. Subjects on drugs such as corticosteroids or antibiotics within 6 months of investigation or antiepileptic drugs (phenytoin or cyclosporine) having an impact on periodontal tissues will be excluded.\n3. Pregnant women (pregnancy may alter the oral flora).\n4. Current smokers and individuals who quit smoking less than 6 months.\n5. Patients who have undergone periodontal therapy within the previous 6 months","30 Years",{"count":446,"type":21},108,"The Klotho gene was initially identified as an aging suppressor gene, but subsequent research revealed its multifaceted functions, encompassing antioxidant defense, anti-inflammatory effects, calcium and phosphorus balance, metabolic regulation, and anti-apoptotic activity. It encodes a single pass transmembrane protein and is expressed primarily in renal tubules. The Klotho protein exists in two forms: membrane-bound and secreted. Membrane Klotho acts as a co-receptor for FGF23, a bone-derived hormone, while secreted Klotho regulates various cell surface glycoproteins, including ion channels and growth factor receptors. Klotho has recently emerged as a potential biomarker for coronary heart disease, with evidence suggesting its involvement in the disease's pathophysiology.\n\nThe red complex, comprising Porphyromonas gingivalis, Treponema denticola and Tannerella forsythia harbors key pathogens in adult periodontal disease. These bacteria possess various virulence factors, including fimbriae, lipopolysaccharides, and proteases in P. gingivalis, which disrupt inflammatory and immune responses and degrade connective tissue proteins. T. forsythia produces a trypsin-like protease, sialidase, hemagglutinin, and BspA, contributing to alveolar bone loss. Meanwhile, T. denticola disrupts the host cell extracellular matrix, penetrates tissue, and dysregulates immunoregulatory factors, further exacerbating periodontal disease. Similarly, Herpes Simplex Virus 1 (HSV-1), human Cytomegalovirus (HCMV) and Epstein Barr Virus (EBV) have been implicated in the pathogenesis of periodontal disease. The expressions of viruses along the red complex bacteria would provide further evidence of periodontal risk in progression of acute coronary artery disease.",[27,449],"Acute Coronary Artery Disease","2026-04-01",{"date":313,"type":36},{"date":453,"type":21},"2026-03-31",{"date":455,"type":21},"2026-11-09",{"name":457,"class":43},"Meenakshi Ammal Dental College and Hospital",{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":51,"sex":466,"minAge":18,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":22,"phases":469,"briefSummary":470,"conditions":471,"keywords":474,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":482,"leadSponsor":484,"locationsCount":69},"100631927","education-based-oral-health-promotion-intervention-during-pregnancy-implementation-protocol-in-bangladesh-100631927","NCT07507045","Education-Based Oral Health Promotion Intervention During Pregnancy: Implementation Protocol in Bangladesh","Oral Health Promotion Intervention During Pregnancy: Bangladesh Perspective","E-OHP","Inclusion Criteria:\n\n* Pregnant women attending ANC services at participating UHCs\n* Gestational age ≤24 weeks at enrolment to allow follow-up\n* Age 18 years or older\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Presence of severe medical or obstetric complications requiring immediate referral\n* Current participation in another behavioural or oral health intervention study\n* Conditions preventing participation in oral examination procedures","FEMALE",{"count":468,"type":21},688,[24],"In Bangladesh, over 95% of pregnant women suffer from gum disease (gingivitis or periodontitis), yet oral health is rarely included in standard pregnancy check-ups. This study tests a new \"Integrated Oral Health Promotion Package\" to see if teaching oral hygiene during routine prenatal visits can improve the health of mothers. Pregnant women (ages 18-45) will be divided into two groups. The intervention group will receive two face-to-face education sessions with a dental assistant, learn a specific tooth-brushing technique, and receive weekly SMS text reminders to brush their teeth. The control group will receive the standard pregnancy care currently offered in Bangladesh. Researchers will track the participants for 12 weeks to see if the education and reminders lead to better brushing habits (twice-daily) and cleaner teeth and gums compared to the standard care group.",[472,27,473],"Pregnancy","Oral Hygiene, Oral Health",[475,472,476,477],"Maternal oral health","Antenatal care","Cluster randomized trial","2026-03-29",{"date":480,"type":36},"2026-04-02",{"date":387,"type":21},{"date":483,"type":21},"2026-11-01",{"name":485,"class":43},"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":490,"acronym":491,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":494,"conditions":495,"keywords":505,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":513,"completionDateStruct":514,"leadSponsor":516,"locationsCount":69},"100629572","oral-health-dento-facial-condition-and-ohrqol-in-subjects-with-mowat-wilson-syndrome-an-epidemiologic-study-100629572","NCT07476417","Oral Health, Dento-facial Condition and OHRQoL in Subjects With Mowat-Wilson Syndrome: an Epidemiologic Study.","ORALMOWAT26","Inclusion Criteria:\n\n* individuals affected by MWS with confirmed molecularly diagnosis of ZEB2 gene variation.\n* written informed consent statement signed by parents\u002Flegal guardians for participation in the study\n\nExclusion Criteria:\n\n* individuals not affected by MWS\n* refusal of parents\u002Flegal guardians to participate in the study",{"count":7,"type":21},"Mowat-Wilson Syndrome (MWS) is a rare syndrome characterized by the presence of facial gestalt and delayed psychomotor development, variably associated with intellectual disability, epilepsy, Hirschsprung's disease (HSCR) and multiple congenital malformations.\n\nAlthough there is evidence of the presence of dental and craniofacial anomalies in MWS, little epidemiological data is available to date.\n\nThe goal of this observational study is to assess oral health and dento-facial phenotype of people affected by Mowat-Wilson Syndrome (MWS). In addition, the Oral Health Related Quality of Life (OHRQoL) will be investigated.",[496,497,27,498,499,500,501,502,503,504],"Mowat-Wilson Syndrome","Dental Caries","Sleep Related Breathing Disorder","Tooth Diseases","Malocclusion","Tooth Abnormalities","Oral Health Related Quality of Life (OHRQoL)","Craniofacial Abnormalities","Oral Mucosal Disease",[506,507,82,508,509,503],"Mowat-Wilson syndrome","dental caries","malocclusion","oral health","2026-03-19",{"date":512,"type":36},"2026-03-24",{"date":450,"type":21},{"date":515,"type":21},"2026-08-30",{"name":517,"class":43},"University of Milan",{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":528,"conditions":529,"keywords":530,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":543,"locationsCount":4},"100628447","development-validation-and-assessment-of-the-diagnostic-accuracy-of-a-questionnaire-for-periodontitis-screening-100628447","NCT07461753","Development, Validation, and Assessment of the Diagnostic Accuracy of a Questionnaire for Periodontitis Screening","Sviluppo, Validazione e Determinazione Della Accuratezza Diagnostica di un Questionario Per lo Screening di Parodontite","Q_ITA","Inclusion Criteria:\n\n* age ≥18 years;\n* ability to read and understand Italian;\n* willingness to participate in the study\n\nExclusion Criteria:\n\n* completely edentulous individuals;\n* subjects who have taken antibiotics within the past 3 months;\n* pregnant women;\n* individuals with contraindications to periodontal probing",{"count":527,"type":21},495,"The present study aims at validating the Italian version of one of the most widely used epidemiological questionnaires for periodontitis screening: the CDC\u002FAAP questionnaire \\[hereafter referred to as the CDC\u002FAAP\\_ITA questionnaire\\].\n\nThe study also aims to develop a modified version of the CDC\u002FAAP questionnaire, enriched with additional questions, and to evaluate its diagnostic accuracy \\[hereafter referred to as the QSIdP questionnaire\\].\n\nThe study will be conducted at the Unità Complessa di Odontoiatria, Azienda Unità Sanitaria Locale (A.U.S.L.) of Ferrara (Director: Prof. Leonardo Trombelli), in collaboration with nine (9) other Italian clinical centers.",[27,161],[531,532,533,534,535],"diagnosis","self-reported questionnaire","validation","sensitivity","specificity","2026-03-06",{"date":538,"type":36},"2026-03-10",{"date":540,"type":21},"2026-04",{"date":542,"type":21},"2027-01",{"name":544,"class":43},"Azienda Unità Sanitaria Locale (A.U.S.L.) Ferrara, Italy",{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":22,"phases":555,"briefSummary":556,"conditions":557,"keywords":558,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":565,"locationsCount":69},"100501744","novosyn-quick-versus-monosyn-quick-suture-material-in-resective-periodontal-surgery-100501744","NCT05813236","NOVOSYN® Quick Versus MONOSYN® Quick Suture Material in Resective Periodontal Surgery","Randomized, Monocentric, Double Blinded, Prospective Study to Evaluate the Early Wound Healing After the Utilization of NOVOSYN® Quick Versus MONOSYN® Quick Suture Material in Resective Periodontal Surgery","NOQMOQS","Inclusion Criteria:\n\n* Adult patient undergoing resective periodontal surgery abd one of the incisions below has been performed:\n* Crestal incision\n* Vertical incision\n* Intrasulcular incision\n* Submarginal incision\n* Written informed consent regarding the data collection for the RCT\n\nExclusion Criteria:\n\n* Emergency surgery.\n* Pregnancy.\n* Breastfeeding\n* Patients taking medication that might affect wound healing.\n* Patients having a condition that might affect wound healing.\n* Patients with hypersensitivity or allergy to the suture material",{"count":554,"type":21},84,[24],"The aim of this study is to prove that Novosyn Quick and Monosyn Quick are equivalent in early wound healing in adult patients undergoing resective periodontal surgery.\n\nIn order to show equivalence between Novosyn Quick and Monosyn Quick EHS, which is composed of 3 parameters: clinical signs of reepithelization, clinical signs of haemostasis and clinical signs of inflammation, will be calculated for each suture 10 ± 5 days postoperatively and cannot differ more than 2 points.\n\nFurthermore, complications, the handling of the suture material, pain, satisfaction of the patient and bacterial contamination of the thread (optional) will also be assessed as secondary objectives.",[183,422,27],[559],"Resective periodontal surgery","2026-03-05",{"date":536,"type":36},{"date":563,"type":36},"2023-06-28",{"date":40,"type":21},{"name":566,"class":292},"Aesculap AG",{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":573,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":575,"enrollmentInfo":576,"targetDuration":4,"studyType":22,"phases":577,"briefSummary":578,"conditions":579,"keywords":581,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":591,"locationsCount":69},"100614681","evaluation-of-the-efficacy-of-subgingival-application-of-lovastatin-gel-as-an-adjunct-to-non-surgical-treatment-of-periodontitis-in-generally-healthy-smokers-and-non-smokers-patients-in-central-europe-100614681","NCT07282756","Evaluation Of The Efficacy Of Subgingival Application Of Lovastatin Gel As An Adjunct To Non-Surgical Treatment Of Periodontitis In Generally Healthy Smokers And Non-Smokers Patients in Central Europe.","Assessment of Changes in Clinical and Radiological Parameters in Gingival Pockets After Subgingival Application of Lovastatin Gel in Combination With SRP Procedure Compared to SRP and Placebo Gel Application in the Treatment of Periodontal Disease in Generally Healthy Non-smokers and Smokers From Central Europe: a Split-mouth Randomized Controlled Trial.","RCT","Inclusion Criteria:\n\n* generally healthy patients\n* diagnosed periodontal disease (at least one pair of non-adjacent sites with PD≥5 mm or CAL ≥4 mm and vertical bone loss ≥ 3 mm)\n* no history of periodontal disease treatment\n* no history of antibiotic use in the past 6 months\n* an eligible tooth must be alive, with no history of endodontic treatment\n* non-smoking (group I) or active smokers (group 2)\n\nExclusion Criteria:\n\n* Statin allergy\n* receiving systemic statin therapy,\n* alcoholics\n* immunocompromised patients\n* pregnant or breastfeeding women.","59 Years",{"count":157,"type":21},[24],"The aim of the study is to evaluate how a gel (1.2% lovastatin) applied under the gum improves the results of classic periodontal treatment (SRP-scaling, root planing).\n\nThe study involves two groups of adults diagnosed with periodontitis: the first group consists of generally healthy individuals who do not smoke tobacco. The second group consists of generally healthy individuals who have been smoking for at least 5 years. Before the study begins, each participant will undergo gum health measurements. Changes in these parameters will be monitored throughout the study. Two teeth will be selected for each participant:\n\n* a gel containing the medication will be applied under the gum of one tooth\n* a gel that looks similar to the medication but does not contain any medicinal substance will be applied under the gum of the second tooth.\n\nBefore applying the gel, each participant will undergo subgingival cleaning (SRP) to remove any debris that may prevent the medicine from working.\n\nThe study will last six months.\n\nExpected results:\n\n* all participants will experience an improvement in the condition of their gums after treatment\n* the effect of treatment will be better in non-smokers than in smokers\n* the treatment outcome will be better in the area where the medicated gel was applied compared to areas where the gel without medicinal substances was applied.",[27,161,303,580],"Smokers",[186,582,583,584,112],"statins","lovastatin","smoking","2026-02-18",{"date":587,"type":36},"2026-02-20",{"date":589,"type":36},"2025-07-11",{"date":40,"type":21},{"name":592,"class":43},"Medical University of Silesia",{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":600,"targetDuration":4,"studyType":22,"phases":601,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":69},"100480249","periodontal-granulation-tissue-preservation-in-surgical-periodontitis-treatment-100480249","NCT05533528","Periodontal Granulation Tissue Preservation in Surgical Periodontitis Treatment","Periodontal Granulation Tissue Preservation in Surgical Periodontal Disease Treatment. A Randomized Clinical Trial","Inclusion Criteria:\n\n* Stage III or IV periodontitis, including all grades.\n* Unresolved deep pockets (probing pocket depth \\[PPD\\] \\>5 mm + BoP) 4 to 6 weeks after non-surgical treatment.\n* Interproximal plaque index \\\u003C35% maintained during periodontal treatment and maintenance.\n* Adherence to periodontal maintenance appointments.\n\nExclusion Criteria:\n\n* Systemic disease contraindicating periodontal surgery.\n* Teeth with incorrect endodontic treatment or restoration.\n* Stage I or II periodontitis.",{"count":7,"type":21},[24],"The objective of this study will be to evaluate a new protocol for the surgical treatment of periodontal disease with two novelties: to make a single incision in the midline of the interproximal area to respect the vascular supply and preserve the granulation tissue with regenerative potential.\n\nThe investigators will carry out a controlled and randomized clinical trial with a control group (n=25; modified Kirkland flap) and a test group (n=25; experimental surgical protocol: incision in the mid-interproximal area of the papilla and preservation of the granulation tissue).\n\nClinical parameters will be taken at the time of surgery and 12 months follow-up: bleeding on probing (BoP), clinical attachment level (CAL), residual probing depth (rPD),Probing pocket depth reduction (PPDr), recession (REC), interproximal gingival recession (iGR), width of keratinized gingiva (KT), gain of supra-alveolar clinical attachment (SUPRA-AG), early wound healing index (EHI).",[30,27,378],"2026-02-16",{"date":606,"type":36},"2026-02-19",{"date":608,"type":36},"2022-05-03",{"date":610,"type":21},"2027-02-01",{"name":612,"class":43},"Universidad de Murcia",{"id":614,"slug":615,"hasResults":12,"nctId":616,"briefTitle":617,"officialTitle":618,"acronym":4,"eligibilityCriteria":619,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":620,"targetDuration":4,"studyType":22,"phases":622,"briefSummary":623,"conditions":624,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":630,"locationsCount":69},"100362312","nipsa-versus-marginal-approach-by-palatal-incision-and-mist-in-periodontal-regeneration-100362312","NCT03997552","NIPSA Versus Marginal Approach by Palatal Incision and MIST in Periodontal Regeneration","Non-Incised Papillae Surgical Approach (NIPSA) Versus Marginal Approach by Palatal Incision and Minimally Invasive Surgical Technique (MIST) in Periodontal Regeneration: a Ramdomized Clinical Trial","Inclusion Criteria:\n\n* patients diagnosed with periodontitis.\n* plaque index and bleeding index of \\\u003C 30%.\n* periodontal lesions with pocket probing depth \\> 5 mm.\n* intrabony defect \\> 3 mm.\n* intrabony defect configuration including a 1 and\u002For 2-wall component, always involving the buccal wall.\n\nExclusion Criteria:\n\n* patients with systemic diseases that contraindicated treatment.\n* third molars.\n* teeth with incorrect endodontic or restorative treatment.",{"count":621,"type":21},60,[24],"Three techniques for periodontal reconstruction will be compared, in which marginal access versus apical access will be carried out.",[161,27,30],{"date":626,"type":36},"2026-02-17",{"date":628,"type":36},"2019-09-06",{"date":610,"type":21},{"name":612,"class":43}]